TransMedics Group, Inc. (NASDAQ:TMDX) Stock Has Average Price Target of $121.10

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned an average recommendation of “Hold” from the thirteen analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $121.00.

Several research analysts recently issued reports on TMDX shares. Weiss Ratings upgraded TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. UBS Group dropped their price target on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a research report on Wednesday, August 5th. Zacks Research cut TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Piper Sandler restated an “overweight” rating and issued a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of TransMedics Group in a research note on Friday, September 11th.

TransMedics Group Price Performance

TransMedics Group stock opened at $77.87 on Monday. The firm has a market capitalization of $2.69 billion, a PE ratio of 20.02, a P/E/G ratio of 1.09 and a beta of 1.94. TransMedics Group has a 52 week low of $60.10 and a 52 week high of $156.00. The firm’s 50-day simple moving average is $86.01 and its 200 day simple moving average is $83.93. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). The business had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business’s revenue was up 20.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.92 earnings per share. On average, equities research analysts predict that TransMedics Group will post 1.46 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other news, Director David Weill purchased 1,336 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were bought at an average cost of $81.63 per share, with a total value of $109,057.68. Following the purchase, the director directly owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.90% of the company’s stock.

Institutional Trading of TransMedics Group

A number of hedge funds have recently bought and sold shares of TMDX. Ascentis Independent Advisors acquired a new position in shares of TransMedics Group during the 1st quarter valued at about $30,000. North Star Investment Management Corp. acquired a new stake in shares of TransMedics Group in the first quarter worth approximately $30,000. Titan Wealth CI Ltd purchased a new stake in TransMedics Group in the fourth quarter valued at approximately $40,000. Silvant Capital Management LLC purchased a new stake in TransMedics Group in the second quarter valued at approximately $26,000. Finally, Whittier Trust Co. of Nevada Inc. increased its position in TransMedics Group by 95.0% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 425 shares of the company’s stock worth $45,000 after purchasing an additional 207 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.